Breast Cancer, An Issue of Surgical Oncology Clinics of North America. The Clinics: Surgery 23-3 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Breast Cancer, An Issue of Surgical Oncology Clinics of North America. The Clinics: Surgery 23-3 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This issue of Surgical Oncology Clinics of North America is devoted to "Breast Cancer" and is edited by Lisa Newman, MD, of the University of Michigan.  Expert authors in this issue review this topic in articles such as: Applications for Breast MRI; Lobular Neoplasia; Epidemiology of Breast Cancer; Percutaneous Ablation of Breast Tumors; Triple Negative Breast Cancer and the Basal Breast Cancer Subtype; Molecular Profiling of Breast Cancer; Surgical Leadership and Standardization of Multidisciplinary Breast Cancer Care; Neoadjuvant/Primary Systemic Therapy for Breast Cancer; Management of the Clinically Node-Negative Axilla in Patients with Primary and Locally-Recurrent Breast Cancer; Management of the Axilla in Patients with Node-Positive Breast Cancer; Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy; Advances in Reconstruction of Mastectomy and Lumpectomy Defects; Nipple-Sparing Mastectomy; and Breast Cancer Disparities.

Read more and order at Breast Cancer, An Issue of Surgical Oncology Clinics of North America. The Clinics: Surgery 23-3

The Top 70 Western European Oncology Contract Research Organisations – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The The Top 70 Western European Oncology Contract Research Organisations Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

It is estimated that clinical development expenditures outsourced by pharmaceutical, medical device and biotechnology companies worldwide in 2012 was approximately Euro 20.6 billion. With greatly developed healthcare and medical systems, highly trained investigators and standardisation across multiple countries, in the form of the European Clinical Trials Directive, Western Europe remains a key region for clinical research.

There are numerous Western European Contract Research Organisations. This report profiles the Top 70 with experience and expertise in cancer.

These companies offer their sponsors a full range of outsourced services including: product development, formulation and manufacturing; clinical trial management (preclinical through phase IV); clinical, medical and safety monitoring; preclinical, toxicology, and clinical laboratory services for processing trial samples; data management, biostatistics and medical writing services; regulatory affairs support; and many other complementary services.

The CRO’s profiled in this report have expertise in all types of cancer e.g. Breast Cancer, NSCLC and SCLC, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Gastric Cancer, Kidney Cancer, Hematologic Malignancies, Paediatric Cancer, Head And Neck Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer, Skin Cancer, Brain Cancer, Bone Metastasis.

They are located right across Europe from the United Kingdom and Ireland to Germany and France.

Profile information for each company typically includes:

– Company Contact Information – Address, Telephone and Fax Numbers, Email and Website Addresses, Social Media Links.
– Key Company Decision Makers – From CEO and Main Board, to Key Senior Managers.
– Specialised fields such as Company Description, Services, Therapeutic Areas, Countries Served, Parent Company, Year Established, Number of Employees and Turnover.

Report Target Market:

1) Contract Research Organisations

Usage: competitive analysis and strategic partner/alliance identification

2) Pharmaceutical, Biotechnology and Medical Device Companies

This report is very useful to pharmaceutical, biotechnology and medical device companies who wish to identify Western Europe’s leading oncology contract research organisations by services offered, size or location.

3) CRO Suppliers

This report is perfect for suppliers of e.g. information technology infrastructure and management information systems who wish to identify top potential customers.

4) CRO, Pharmaceutical, Biotechnology and Medical Device Associations

The Top 70 Western European Oncology Contract Research Organisations is a useful reference tool for CRO, pharmaceutical, biotechnology and medical device associations.

Note: Most people will be aware of some of the major Western European Oncology Contract Research Organisations like Specialized Medical Services-oncology BV (SMS-oncology) but this report looks at all 70 of the Top Oncology CRO’s there – companies like Orion Clinical Services Limited – founded in 1997 and headquartered in Slough, United Kingdom, 50% of this full-service CRO’s experience is in oncology (Acute and Chronic Myeloid and Lymphoblastic Leukaemia, Bladder Cancer, Breast Cancer, Metastatic Breast Cancer, Colorectal Cancer, Gastrointestinal Stromal Tumour, Head and Neck Tumours, Hepatic Cancer – Primary and Secondary, Lymphoma including Non-Hodgkin's, Malignant Glioma, Melanoma, Non-small Cell Lung Cancer, Oesophageal Cancer, Oesteosarcoma, Oral Cavity Cancer, Ovarian Cancer, Pancreatic Cancer, Prostatic Cancer (including HRPC), Renal Cell Cancer, Soft Tissue Sarcoma, Superficial Metastatic Tumours). This means that nearly all of Orion’s staff has experience of cancer studies. It also means that their systems and processes have been designed to meet the needs of this challenging therapeutic area. The company is led by Dr Alan Irvine, CEO.

Report data field structure is as follows:

– Company Name
– Mailing Address
– Street Address
– Telephone
– Fax
– Email (Company & Executive)
– Website
– Social Media Links
– Parent Company Name
– Year Established
– Number of Employees
– Key Executives
– Company Description
– Services
– Therapeutic Areas
– Countries Served
– Turnover €m
– Location Status
– Ownership

Research Facts is a world leader in life sciences publishing. It was established in Dublin, Ireland in 2004. Its partners have over fifty years combined experience in the business information industry. Research Facts' customers include most of the world's major diagnostics, pharmaceutical, biotechnology and medical device companies e.g. Abbott Laboratories, Alcon, Allergan, Axis-Shield, Baxter, Bayer, B. Braun, BD, Biomet, Boehringer Ingelheim, CareFusion, Covance, Covidien, Edwards Lifesciences, Fresenius, GE Healthcare, Genzyme, HemoCue, Intuitive Surgical, Ipsen, Medtronic, Merit Medical Systems, Millipore, Mölnlycke Health Care, Novartis, Paul Hartmann, Philips Medical, Qiagen, Siemens Healthcare, Smith & Nephew, Synthes, Teleflex, Teva, Zentiva etc..

Research Facts has customers right across the globe e.g. Austria, Australia, Belgium, Brazil, Canada, Cyprus, Czech Republic, Denmark, France, Germany, Finland, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Kuwait, Luxembourg, Mauritius, Netherlands, Pakistan, Peru, Portugal, Russia, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, and the United States.

Research Facts' reports help you make informed decisions about the markets and organisations that affect your business.

– Learn more about your target markets and target companies
– Top level research on all major players in a market
– See which organisations dominate your major markets
– Get detailed information on particular organisations

Read more and order at The Top 70 Western European Oncology Contract Research Organisations

Cutaneous Melanoma, An Issue of Clinics in Plastic Surgery. The Clinics: Surgery 37-1 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Cutaneous Melanoma, An Issue of Clinics in Plastic Surgery. The Clinics: Surgery 37-1 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

In the 10 years since malignant melanoma was last covered in Clinics in Plastic Surgery, significant changes have occurred in the diagnosis and treatment of this disease.  Sentinel lymph node biopsy has now become the standard of care in melanoma.   The staging system was totally revamped in 2002, taking into account the significance of ulceration and the information gained during sentinel node biopsy.  With more than 60,000 patients diagnosed each year with malignant melanoma, the plastic surgeon must continue to be pivotal in the management of patients with this disease, coordinating care among the specialists and being integral in all aspects of surgery and follow-up.

Read more and order at Cutaneous Melanoma, An Issue of Clinics in Plastic Surgery. The Clinics: Surgery 37-1

Advances in Cancer Research, Vol 102 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Advances in Cancer Research, Vol 102 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including tumor dormancy, micro RNA, tumor angiogenesis, cancer in mouse models, liposome based chemo and autoimmunotherapy, signaling in angiogenesis, targeted cancer therapy, and regulatory t-cells.

Read more and order at Advances in Cancer Research, Vol 102

2016-2021 Emerging US Point-of-Care/POC Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The 2016-2021 Emerging US Point-of-Care/POC Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

2016-2021 Emerging US Point-of-Care/POC Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers – Supplier Shares, Competitive Strategies, Country Segment Forecasts, Innovative Technologies, Instrumentation Review'

This new 418-page report contains 42 tables, and provides a comprehensive analysis of thePOC coagulation testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC coagulation market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis

– Review of nine POC market segments, including their dynamics, trends, structure,
size, growth and major suppliers.

– Five-year test volume and reagent sales forecasts for coagulation procedures
by market segment:

– Physician Offices/Group Practices
– Emergency Rooms
– Operating/Recovery Suites
– ICUs/CCUs
– Cancer Clinics
– Ambulatory Care Centers
– Surgery Centers
– Nursing Homes
– Birth Centers

Sales and Market Share Analysis

– Sales and market shares of major coagulation reagent and instrument suppliers.

Current and Emerging Products

– Analysis of coagulation procedures performed in POC testing locations.
– Review of leading coagulation analyzers, both currently marketed and
those in development, including their operating characteristics, features and selling prices.

Technology Review

– Emerging technologies and their applications for POC testing.
– Comprehensive listings of companies developing or marketing coagulation
testing technologies and products, by assay.

Competitive Assessments

– Assessments of major suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, joint ventures,
and new products in R&D.

Strategic Recommendations

– Specific opportunities for new coagulation instruments and reagent systems with potentially
significant market appeal during the next five years.
– Design criteria for POC testing products.
– Alternative business expansion strategies.
– Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and proprietary data files.

Contains 418 pages and42 tables

Read more and order at 2016-2021 Emerging US Point-of-Care/POC Coagulation Testing Market: Physician Offices, Emergency Rooms, Operating Suites, ICU/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers

Advances in Cancer Research, Vol 113 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Advances in Cancer Research, Vol 113 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.

  • 113th volume of Advances in Cancer Research
  • Expert authors
  • Chapters on topics including microRNA regulatory network, multifaceted oncoprotein tax, and underlying chromosomal translocations

Read more and order at Advances in Cancer Research, Vol 113

Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics. The Clinics: Internal Medicine 37-1 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics. The Clinics: Internal Medicine 37-1 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

An estimated 234,000 new cases of prostate cancer will be diagnosed in the United States this year, making it one of the most common cancers affecting American men; however, it can be a controversial disease to diagnose and treat now that there is research abounding for both "watchful waiting” and aggressive treatments. Dr. Oh supplies balanced information, with articles on: Prostate Cancer: To Screen or Not To Screen?; High Intensity Focused Ultrasound: Ready for Primetime?; The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy; Primary and Salvage Prostate Cancer Cryotherapy; and  The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy, to name a few. The state-of-the art information presented in this issue make is must-have for all urologists.

Read more and order at Advances and Controversies in Prostate Cancer, An Issue of Urologic Clinics. The Clinics: Internal Medicine 37-1

US POC/Point-of-Care Coagulation Testing Market 2021: Physician Offices, Emergency Rooms, Operating Suites, ICUs/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The US POC/Point-of-Care Coagulation Testing Market 2021: Physician Offices, Emergency Rooms, Operating Suites, ICUs/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

This new 418-page report contains 42 tables, and provides a comprehensive analysis of thePOC coagulation testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC coagulation market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis

– Review of nine POC market segments, including their dynamics, trends, structure,
size, growth and major suppliers.

– Five-year test volume and reagent sales forecasts for coagulation procedures
by market segment:

– Physician Offices/Group Practices
– Emergency Rooms
– Operating/Recovery Suites
– ICUs/CCUs
– Cancer Clinics
– Ambulatory Care Centers
– Surgery Centers
– Nursing Homes
– Birth Centers

Sales and Market Share Analysis

– Sales and market shares of major coagulation reagent and instrument suppliers.

Current and Emerging Products

– Analysis of coagulation procedures performed in POC testing locations.
– Review of leading coagulation analyzers, both currently marketed and
those in development, including their operating characteristics, features and selling prices.

Technology Review

– Emerging technologies and their applications for POC testing.
– Comprehensive listings of companies developing or marketing coagulation
testing technologies and products, by assay.

Competitive Assessments

– Assessments of major suppliers and emerging market entrants,
including their sales, product portfolios, marketing tactics, joint ventures,
and new products in R&D.

Strategic Recommendations

– Specific opportunities for new coagulation instruments and reagent systems with potentially
significant market appeal during the next five years.
– Design criteria for POC testing products.
– Alternative business expansion strategies.
– Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and proprietary data files.

Contains 418 pages and42 tables

Read more and order at US POC/Point-of-Care Coagulation Testing Market 2021: Physician Offices, Emergency Rooms, Operating Suites, ICUs/CCUs, Cancer Clinics, Ambulatory Care Centers, Surgery Centers, Nursing Homes, Birth Centers

PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide. Sales of the PD-1/PD-L1 therapy class have grown from $84m in 2014 to $6,292m in 2016, with five PD-1/PD-L1 inhibitors currently approved across a variety of tumor indications. Despite the success of these products, developers continue to face clinical and commercial challenges. Nonetheless, the broad applicability and strong initial success of PD-1/PD-L1 inhibitors in oncology means that companies are actively seeking ways to differentiate their products and increase their market share.

Note: The analyst Dustin Phan presented these slides in Tokyo and Osaka during July 2017.

Read more and order at PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology

Oncology Market Opportunities, Strategies, and Forecasts, 2006 To 2012 – Healthcare, Healthcare Services, Oncology, Therapeutic Area Industries

The Oncology Market Opportunities, Strategies, and Forecasts, 2006 To 2012 Report has been published. It provides updated in 2018 year analysis of industries from Healthcare, Healthcare Services, Oncology, Therapeutic Area Markets.

Between 2000 and 2020, the World Health Organization is predicting a 50% rise in the global incidence of cancer. Fortunately for those diagnosed with cancer between now and 2020, cancer treatments are also projected to evolve along with the cancer market, creating options for the afflicted.

However, these options come at a significant price. Prescription drug costs have spiraled from $12 billion annually in 1980 to $179 billion in 2003, according to the Center for Medicare and Medicaid Services. In addition, cancer drugs will be the fastest-growing part of the drug market for the next five years, with costs rising 20 percent a year, according to many analysts. Every major drug maker is now investing heavily in oncology, rushing to capitalize on new research about the way cancer cells reproduce.

With the cancer market struggling with few new drugs-only 1 of 20 cancer drugs developed reach the market-and expensive drugs, the FDA hopes to develop new tests to assess a patient's cancer. Instead of the old test that simply uses X-rays, the FDA wants to employ imaging, blood tests, as well as other techniques to better assess a patient's progression of cancer. X-rays only measure the size of the tumor, and a smaller tumor after use of a drug does not necessarily mean the tumor is any less dangerous. With these new tests to measure success against cancer, cancer drugs would be able to make it to market quicker.

Using chemotherapy as an example, patients with advanced disease used to live an average of one year, at a cost of $63 for an initial 8-week treatment. A newer drug regimen has extended survival to 21 months, but at a cost of $12,000. Situations like this stress the ailing U.S. health care system, raising questions about the cost of end-of-life care.

The oncology market will grow steadily due to numerous factors, including the aging population, new treatments available, the unraveling of the genetics behind cancer, and the fact that cancer is a significant disease with many variations.

The oncology market forecasts show an increase from 18 million in 2004 to over 195 Million in 2012.

Key Topics
– Oncology Market Shares, Forecasts, and Driving Forces
– Nanotechnology Cancer Treatment Market Forecasts
– Angiogenesis
– Gold Nanoparticles And Lasers Cancer Surgery
– SpectRx
– Cancers
Lung
Breast
Colorectal
Ovarian
Prostate
– Tunable Laser Market Analysis
– Ekips Asthma Testing
– Ekips Technologies
– Given Diagnostic System

Report Methodology
This is the 271st report in a series of market research reports that provide forecasts in communications, telecommunications, the internet, computer, software, and telephone equipment. The project leaders take direct responsibility for writing and preparing each report. They have significant experience preparing industry studies. Forecasts are based on primary research and proprietary data bases. Forecasts reflect analysis of the market trends in the segment and related segments. Unit and dollar shipments are analyzed through consideration of dollar volume of each market participation in the segment. Market share analysis includes conversations with key customers of products, industry segment leaders, marketing directors, distributors, leading market participants, and companies seeking to develop measurable market share. Over 200 in-depth interviews are conducted for each report with a broad range of key participants and opinion leaders in the market segment.

Read more and order at Oncology Market Opportunities, Strategies, and Forecasts, 2006 To 2012